Compare FCNCP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCNCP | CRNX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 18141 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | FCNCP | CRNX |
|---|---|---|
| Price | $21.38 | $36.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $76.63 |
| AVG Volume (30 Days) | 28.5K | ★ 1.1M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | N/A | $184.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.30 | $24.10 |
| 52 Week High | $22.86 | $57.99 |
| Indicator | FCNCP | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 46.73 |
| Support Level | $21.40 | $33.23 |
| Resistance Level | $22.06 | $45.32 |
| Average True Range (ATR) | 0.28 | 1.68 |
| MACD | 0.01 | 0.50 |
| Stochastic Oscillator | 73.37 | 76.62 |
First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.